Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2025 results , with sales up 7.5% year on year to $805 million. The company expects the full year’s revenue to be ...
My estimations suggest that the U.S. government's cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results